RIPK1 and ischemia: Subsequently, we intracerebroventricularly administered the RIP1 kinase inhibitor Nec-1, the autophagy inhibitor 3-MA, and the caspase-3 inhibitor Ac-DMQD-CHO 1 h before ischemia to investigate their effects.